<DOC>
	<DOCNO>NCT00111020</DOCNO>
	<brief_summary>This treatment protocol allow doctor treat advance kidney cancer investigational drug call sorafenib , BAY43-9006 , study clinical trial kidney cancer kind cancer . This treatment protocol clinical trial sorafenib compare another equal treatment . All patient protocol treat sorafenib . In addition , data patient participate protocol provide additional information drug .</brief_summary>
	<brief_title>Treatment Protocol Use Sorafenib Patients With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients advance ( unresectable , recurrent metastatic ) RCC Patients reasonably likely benefit treatment sorafenib single agent therapy Patients ECOG performance status 02 Patients require systemic anticancer therapy ( except bisphosphonates ) take sorafenib Patients vascular disease wet macular degeneration , vasculitis , new peptic ulcer , may enrol require close monitoring accordance establish medical practice Patients currently enrol , eligible , access , sorafenib clinical trial Patients participate sorafenib trial Patients prior therapy investigational agent ( ) within last four week prior study entry Life expectancy less two month Patients cardiac arrhythmias great grade 1 NCI CTCAE , Version 3.0 Patients active coronary artery disease ischemia Patients ChildPugh class C hepatic impairment Patients severe renal impairment require dialysis Patients active uncontrolled hypertension Patients recent active bleeding diathesis</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>